AstraZeneca sets ambition to deliver $80 billion Total Revenue by …
May 21, 2024 · AstraZeneca’s ambitions, forecasts and targets in this announcement (the “Financial Ambition Statements”) are derived from AstraZeneca’s most recent risk-adjusted mid- and long-term plans, adjusted for developments in the business since those plans were finalised.
Investor Relations - AstraZeneca
This website is intended for people seeking information on AstraZeneca's worldwide business. Our country sites can be located in the AZ Network.
AstraZeneca to acquire Fusion to accelerate the development of …
Mar 19, 2024 · AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
Q1 2024 results - AstraZeneca
Apr 25, 2024 · “AstraZeneca had a very strong start in 2024 with substantial Total Revenue growth of 19% in the first quarter. Our strong pipeline momentum continued and already this year we announced positive trial results for Imfinzi and Tagrisso that were unprecedented in lung cancer, the data from both of these studies will be presented during the ASCO ...
9M and Q3 2023 results - AstraZeneca
Nov 9, 2023 · Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: “Our company continued its strong growth trajectory in the third quarter with Total Revenue from our non‑COVID-19 medicines up 13% compared to last year.
AstraZeneca to acquire Icosavax, including potential first-in-class …
Dec 12, 2023 · The proposed acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca’s Vaccines & Immune Therapies late-stage pipeline with Icosavax’s lead investigational vaccine candidate, IVX-A12.
Stock Exchange announcements - AstraZeneca
The announcements set out on this page have been notified to the London Stock Exchange through the Regulatory News Service.
AstraZeneca plans $1.5 billion manufacturing facility for antibody …
May 20, 2024 · Png Cheong Boon, Chairman, EDB said: "We welcome AstraZeneca's decision to establish a manufacturing presence in Singapore for the first time. It will also be a first for AstraZeneca – an end-to-end manufacturing facility for novel antibody drug conjugates that enables precision therapy for cancer.
Eplontersen demonstrated sustained benefit in Phase III
Mar 27, 2023 · AstraZeneca in CVRM Cardiovascular, Renal and Metabolism (CVRM), part of BioPharmaceuticals, forms one of AstraZeneca’s three disease areas and is a key growth driver for the Company.
AstraZeneca advances science of infectious disease protection at …
Oct 16, 2024 · Beyfortus (nirsevimab) is a single dose long-acting antibody, developed and commercialised in partnership by AstraZeneca and Sanofi using AstraZeneca’s YTE extended-half-life technology. It is designed to protect infants born during or entering their first RSV season and for children up to 24 months of age who remain vulnerable to severe RSV ...
- Some results have been removed